RxDoctor Payments DataLook up a doctor →

David Sutton, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1447252523

Payments from drug & device makers

$3,127,264in general payments, 2019–2025

Across 2,670 payments — averaging $1171.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$537K
  • Medtronic$497K
  • Lilly USA, LLC$422K
  • Sanofi US Services Inc.$410K
  • Novartis$357K
  • Regeneron$330K
  • plus $575K from 51 others
$4,329in research payments, 2019–2025

Across 1 payment — averaging $4329.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly10$537,111
Medtronic(2 entities)139$496,864
Lilly USA, LLC636$422,060
Sanofi US Services Inc.29$409,945
Novartis22$356,846
Regeneron21$329,679
Novo Nordisk420$204,427
Alnylam Pharmaceuticals Inc.263$148,642
Abbott243$61,161
AbbVie47$39,282
Boehringer Ingelheim97$36,241
Amarin Pharma, Inc.15$20,131
Valeritas, Inc.39$19,638
Pfizer1$13,559
Dexcom, Inc.25$7,704
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Zealand Pharma US, Inc.9$4,119
Insulet Corporation157$2,241
Amgen(2 entities)87$1,513
Sanofi-aventis U.S. LLC60$1,249
Corcept Therapeutics37$1,226
Mannkind Corporation39$1,110
Bayer55$916
Boehringer Ingelheim International GmbH8$719
Xeris Pharmaceuticals, Inc.39$718
Radius Health, Inc.29$555
AstraZeneca(2 entities)26$465
IBSA Pharma Inc.28$375
Ultragenyx Pharmaceutical Inc.6$364
Ascendis Pharma Endocrinology Inc9$261
Cequr Corporation1$235
Tandem Diabetes Care, Inc.13$197
Kyowa Kirin, Inc.5$84
Ipsen Biopharmaceuticals, Inc5$77
Senseonics, Incorporated2$68
Madrigal Pharmaceuticals3$67
Boston Scientific2$62
Recordati_rare_diseases_inc.4$60
Antares Pharma, Inc.3$59
Rhythm Pharmaceuticals, Inc.2$57
Merck4$55
Shire North American Group Inc4$48
Astellas Pharma US Inc3$48
Amneal Pharmaceuticals LLC3$46
Johnson & Johnson4$46
Lifescan, Inc.3$44
Chiesi USA, Inc.1$35
Endo Pharmaceuticals Inc.2$25
BETA Bionics, Inc.1$23
Amryt Pharma Holdings Ltd1$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$18
Nevro Corp.1$16
Eisai Inc.1$16
Almatica Pharma LLC1$16
Neurocrine Biosciences, Inc.1$14
Vivus LLC1$14
Sequel Med Tech, LLC1$14

How this compares

$3,127,264 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$214,452
Medicare patients
613
Services billed
2,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jacksonville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →